Not for Human Consumption
Not For Human ConsumptionGrey market peptides have built a parallel pharmaceutical infrastructure under the thinnest regulatory pretense. The data reveals a cultural contradiction that extends far beyond weight loss.SomewhereJan 01, 20261371312ShareThe FDA classifies BPC-157 as Category 2 (ineligible for compounding) while Telegram communities with 35,000 members crowdsource third-party lab testing at $850 per batch. Eli Lilly’s retatrutide achieves 28.7% weight loss in Phase 3 trials while Chinese suppliers ship enough semaglutide API to produce over one billion starter doses. At a December 2025 San Francisco party called the “Chinese Peptide Rave,” attendees learned injection technique in a co-working space that bills itself as a “self-governed vertical village.” The coherence…
